Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax gets Nasdaq extension to April 2024 for minimum bid compliance

Virpax Pharmaceuticals, Inc.

Received 180-day extension from Nasdaq to April 8, 2024 to meet $1.00 minimum bid price.
Previously failed to regain compliance by Oct 9, 2023 after initial April 10, 2023 notice.
Must maintain bid price of at least $1.00 for ten consecutive business days to comply.
Considering options including reverse stock split to maintain Nasdaq listing.
Stock continues trading on Nasdaq Capital Market under symbol VRPX with no immediate impact.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 10, 2023, the Company received written notification from Nasdaq granting the Company’s request for a 180-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved if at any time prior to April 8, 2024 the closing bid price of the Company’s common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will notify the Company that it has regained compliance with the Minimum Bid Price Requirement and the matter will be closed; however, Nasdaq has discretion to require the Company to maintain a bid price of $1.00 for a period

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001013762-23-003163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.